Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02401295 | ATRA, Celecoxib, and Itraconazole as Maintenance | completed | Phase 1 | 1 | University of IowaOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
| 1 |
| Feb 20, 2017 |
| clinicaltrials |
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | completed | Phase 1 | 13 | Baylor College of MedicineOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT00323323 | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | completed | Phase 1 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02697552 | Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma | completed | Phase 1 | 13 | HUYABIO International, LLC.INDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00854152 | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 121 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01356173 | Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma | completed | Phase 1 | 10 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01432353 | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | completed | Phase 1 / Phase 2 | 37 | Emory UniversityOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT00901069 | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | completed | Phase 1 | 12 | Shams ShakilOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01580371 | Safety and Pharmacokinetic Profile of CKD-581(CKD-581) | completed | Phase 1 | 39 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01718899 | Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | completed | Phase 1 | 22 | OncoPep, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT00434629 | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | completed | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT00407303 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 24 | Gemin XINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02018874 | A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine(INPAKT) | completed | Phase 1 | 52 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01114282 | Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | completed | Phase 1 | 11 | Stanford UniversityOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02017613 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies(PI3K) | completed | Phase 1 | 35 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Jun 24, 2016 | clinicaltrials |
| NCT00990717 | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00698776 | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | completed | Phase 1 | 6 | Yale UniversityOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | completed | Phase 1 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT00299767 | Phase I Study of Sequential Cord Blood Transplants | completed | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | completed | Phase 1 | 20 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | May 11, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01212380 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | completed | Phase 1 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT00644124 | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | completed | Phase 1 | 25 | SanofiINDUSTRY | 1 | May 6, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2017source: clinicaltrials